



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Duan et al. (as amended)

Docket No.: PZ045P1D1

Application No.: 10/733,368

Confirmation No.: 2585

Filed: December 12, 2003

Art Unit: 1644

For: Antibodies Against HCE3C63 Polypeptide (as
amended)

Examiner: S. Jalla

REPLY AND AMENDMENTS UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed December 20, 2005 (Paper No. 100505), please enter the following election and amendments. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet, with appropriate fee(s); (b) a Substitute Sequence Listing in written (two CDs labeled "Copy 1 Replacement 03/15/2006" and "Copy 2 Replacement 03/15/2006") and computer readable (one CD labeled "CRF Replacement 03/15/2006") forms; (c) a Transmittal and Submission Under 37 C.F.R. §§ 1.52(e) and 1.821(c); (d) a Statement Under 37 C.F.R. §§ 1.821 and 1.825; (e) Supplemental Application Data Sheet to correct inventorship pursuant to 37 C.F.R. §1.48(b) (*Non-provisional application - fewer inventors due to amendment or cancellation of claims*); (f) Statement Under 37 C.F.R. § 3.73, Revocation of Prior Powers of Attorney or Authorizations of Agent, and Power of Attorney or Authorization of Agent; (g) Exhibit A — an alignment showing the functional domains shared by HCE3C63 and DBCCR1, Exhibit B — PROSITE analysis of HCE3C63, Exhibit C — PROSITE analysis of DBCCR1, and Exhibit D — sequence alignment between EMBL accession number AL035289 and SEQ ID NO:35; and (h) a copy of the Notice to Comply.

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims begin on page 3 of this paper.
- Remarks begin on page 7 of this paper.

Insertions are shown by underlining. Deletions are shown by ~~strikethrough~~.